Shanghai Medicilon Inc. Sustainability Profile
Shanghai Medicilon Inc., often referred to simply as Medicilon, is a leading contract research organisation (CRO) headquartered in Shanghai, China. Established in 2004, the company has rapidly expanded its operational footprint across major regions, including North America and Europe, positioning itself as a key player in the pharmaceutical and biotechnology sectors. Medicilon offers a comprehensive suite of services, including drug discovery, preclinical development, and laboratory services, distinguished by its commitment to quality and innovation. The company has achieved significant milestones, such as the successful completion of numerous projects that have advanced drug development for various therapeutic areas. With a strong market presence and a reputation for excellence, Shanghai Medicilon Inc. continues to support clients in navigating the complexities of drug development, making it a trusted partner in the life sciences industry.
DitchCarbon Score
How does Shanghai Medicilon Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Shanghai Medicilon Inc.'s score of 20 is lower than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Shanghai Medicilon Inc.'s reported carbon emissions
Shanghai Medicilon Inc., headquartered in China, currently does not report any specific carbon emissions data, as there are no available figures for emissions in kg CO2e. Additionally, the company has not established any documented reduction targets or climate pledges. As such, there are no specific commitments or initiatives related to carbon emissions reduction to highlight at this time. In the context of the industry, many organisations are increasingly focusing on sustainability and climate commitments, often setting ambitious targets to reduce their carbon footprints. However, without specific data or commitments from Shanghai Medicilon Inc., it is unclear how they align with these industry trends.
How Carbon Intensive is Shanghai Medicilon Inc.'s Industry?
How Carbon Intensive is Shanghai Medicilon Inc.'s Location?
Shanghai Medicilon Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Shanghai Medicilon Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
